-
Development of StaphVAX, a polysaccharide conjugate vaccine against S. aureus infection: from the lab bench to phase III clinical trials.
Vaccine. 2004 Feb 17;22(7):880-7
PMID: 15040941
-
Immunochemical properties of the staphylococcal poly-N-acetylglucosamine surface polysaccharide.
Infect Immun. 2002 Aug;70(8):4433-40
PMID: 12117954
-
The role of epitope specificity in the human opsonic antibody response to the staphylococcal surface polysaccharide poly N-acetyl glucosamine.
J Infect Dis. 2005 Dec 1;192(11):2012-9
PMID: 16267775
-
Antibodies: can they protect against HIV infection?
Curr Drug Targets Infect Disord. 2005 Jun;5(2):95-111
PMID: 15975016
-
Antibodies against a truncated Staphylococcus aureus fibronectin-binding protein protect against dissemination of infection in the rat.
Vaccine. 2001 May 14;19(25-26):3376-83
PMID: 11348701
-
Broadly protective vaccine for Staphylococcus aureus based on an in vivo-expressed antigen.
Science. 1999 May 28;284(5419):1523-7
PMID: 10348739
-
Identifying epitopes of HIV-1 that induce protective antibodies.
Nat Rev Immunol. 2004 Mar;4(3):199-210
PMID: 15039757
-
Vancomycin-resistant enterococci: a road map on how to prevent the emergence and transmission of antimicrobial resistance.
Chest. 2003 May;123(5 Suppl):504S-18S
PMID: 12740236
-
Epstein Barr virus transformation of peripheral blood B cells secreting antibodies reactive with cell surface antigens.
Autoimmunity. 1990;8(2):149-58
PMID: 1966543
-
Production and characterization of a set of mouse-human chimeric immunoglobulin G (IgG) subclass and IgA monoclonal antibodies with identical variable regions specific for Pseudomonas aeruginosa serogroup O6 lipopolysaccharide.
Infect Immun. 1998 Sep;66(9):4137-42
PMID: 9712759
-
Protective antibodies and endemic dimorphic fungi.
Curr Mol Med. 2005 Jun;5(4):435-42
PMID: 15977999
-
Preparation of toxic shock syndrome toxin-1.
Methods Enzymol. 1988;165:37-43
PMID: 3231114
-
Long-term outcome and quality of care of patients with Staphylococcus aureus bacteremia.
Eur J Clin Microbiol Infect Dis. 2004 Mar;23(3):157-62
PMID: 14986158
-
Antigenic determinants of Staphylococcus aureus type 5 and type 8 capsular polysaccharide vaccines.
Infect Immun. 1998 Oct;66(10):4588-92
PMID: 9746554
-
Antimicrobial resistance: the example of Staphylococcus aureus.
J Clin Invest. 2003 May;111(9):1265-73
PMID: 12727914
-
Open-label, dose escalation study of the safety and pharmacokinetic profile of tefibazumab in healthy volunteers.
Antimicrob Agents Chemother. 2005 Mar;49(3):959-62
PMID: 15728889
-
Comparative opsonic and protective activities of Staphylococcus aureus conjugate vaccines containing native or deacetylated Staphylococcal Poly-N-acetyl-beta-(1-6)-glucosamine.
Infect Immun. 2005 Oct;73(10):6752-62
PMID: 16177353
-
Monoclonal antibodies to CNA, a collagen-binding microbial surface component recognizing adhesive matrix molecules, detach Staphylococcus aureus from a collagen substrate.
J Biol Chem. 2000 Dec 22;275(51):39837-45
PMID: 10991941
-
The construction and use of a human-mouse myeloma analogue suitable for the routine production of hybridomas secreting human monoclonal antibodies.
Hybridoma. 1987 Dec;6(6):611-25
PMID: 3436625
-
The intercellular adhesion (ica) locus is present in Staphylococcus aureus and is required for biofilm formation.
Infect Immun. 1999 Oct;67(10):5427-33
PMID: 10496925
-
Recurrent variable region gene usage and somatic mutation in the human antibody response to the capsular polysaccharide of Streptococcus pneumoniae type 23F.
Infect Immun. 2002 Aug;70(8):4083-91
PMID: 12117915
-
Depletion of B cells in vivo by a chimeric mouse human monoclonal antibody to CD20.
Blood. 1994 Jan 15;83(2):435-45
PMID: 7506951
-
Opsonophagocytic activity induced by chimeric antibodies of the four human IgG subclasses with or without help from complement.
Scand J Immunol. 1994 Jun;39(6):581-7
PMID: 8009174
-
Characterization of a humanized monoclonal antibody recognizing clumping factor A expressed by Staphylococcus aureus.
Infect Immun. 2005 Aug;73(8):5229-32
PMID: 16041045
-
Promises and pitfalls of Pseudomonas aeruginosa lipopolysaccharide as a vaccine antigen.
Carbohydr Res. 2003 Nov 14;338(23):2549-56
PMID: 14670716
-
Human monoclonal antibodies to Pseudomonas aeruginosa alginate that protect against infection by both mucoid and nonmucoid strains.
J Immunol. 2004 Nov 1;173(9):5671-8
PMID: 15494518
-
Therapeutic antibodies.
Curr Mol Med. 2004 Aug;4(5):539-47
PMID: 15267225
-
Application of vaccine technology to prevention of Pseudomonas aeruginosa infections.
Expert Rev Vaccines. 2005 Oct;4(5):645-56
PMID: 16221066
-
A crucial role for exopolysaccharide modification in bacterial biofilm formation, immune evasion, and virulence.
J Biol Chem. 2004 Dec 24;279(52):54881-6
PMID: 15501828
-
Anticancer antibodies.
Am J Clin Pathol. 2003 Apr;119(4):472-85
PMID: 12710120
-
Palivizumab: a review of its use as prophylaxis for serious respiratory syncytial virus infection.
Paediatr Drugs. 2004;6(3):177-97
PMID: 15170364
-
Infliximab treatment of rheumatoid arthritis and Crohn's disease.
Ann Pharmacother. 2003 Sep;37(9):1256-65
PMID: 12921510
-
Staphylococcus aureus sepsis and the Waterhouse-Friderichsen syndrome in children.
N Engl J Med. 2005 Sep 22;353(12):1245-51
PMID: 16177250
-
Antibacterial monoclonal antibodies and the dawn of a new era in the control of infection.
Surv Synth Pathol Res. 1984;3(2):119-30
PMID: 6438759
-
Nosocomial bloodstream infections in US hospitals: analysis of 24,179 cases from a prospective nationwide surveillance study.
Clin Infect Dis. 2004 Aug 1;39(3):309-17
PMID: 15306996
-
Pathogenesis of infections related to intravascular catheterization.
Clin Microbiol Rev. 1993 Apr;6(2):176-92
PMID: 8472248
-
Immunochemical characterization of two surface polysaccharides of Bacteroides fragilis.
Infect Immun. 1991 Jun;59(6):2075-82
PMID: 2037368